Development
Novartis AG
NVS
$118.15
$1.311.12%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 7.66% | -0.59% | -8.64% | -17.62% | -18.25% |
| Total Other Revenue | -2.79% | 8.55% | 2.82% | -1.92% | 0.32% |
| Total Revenue | 7.36% | -0.36% | -8.35% | -17.25% | -17.81% |
| Cost of Revenue | 6.40% | -2.45% | -11.98% | -26.11% | -26.81% |
| Gross Profit | 7.70% | 0.38% | -7.01% | -13.67% | -14.10% |
| SG&A Expenses | 2.85% | -5.77% | -11.65% | -18.69% | -18.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 28.68% | -165.89% | -142.94% | -2.36% | -37.07% |
| Total Operating Expenses | 5.48% | -11.18% | -13.82% | -18.57% | -19.40% |
| Operating Income | 12.78% | 35.12% | 8.33% | -13.36% | -12.85% |
| Income Before Tax | 27.11% | -63.14% | -65.50% | -72.50% | -72.54% |
| Income Tax Expenses | -51.15% | -29.82% | -25.95% | -48.39% | -46.77% |
| Earnings from Continuing Operations | 41.71% | -65.55% | -68.55% | -74.67% | -74.81% |
| Earnings from Discontinued Operations | 1,438.38% | 63.67% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -300.00% | -200.00% | -166.67% | -100.00% |
| Net Income | 113.52% | -64.05% | -66.72% | -70.95% | -71.05% |
| EBIT | 12.78% | 35.12% | 8.33% | -13.36% | -12.85% |
| EBITDA | 9.93% | 24.78% | 5.89% | -10.89% | -11.34% |
| EPS Basic | 125.61% | -61.77% | -64.90% | -69.72% | -70.30% |
| Normalized Basic EPS | 21.66% | -40.07% | -50.12% | -58.51% | -60.47% |
| EPS Diluted | 125.36% | -61.65% | -64.77% | -69.62% | -70.23% |
| Normalized Diluted EPS | 21.75% | -40.06% | -50.11% | -58.51% | -60.48% |
| Average Basic Shares Outstanding | -5.30% | -4.41% | -3.98% | -3.06% | -2.07% |
| Average Diluted Shares Outstanding | -5.31% | -4.42% | -4.04% | -3.11% | -2.12% |
| Dividend Per Share | 13.24% | 1.77% | 1.77% | 1.77% | 1.77% |
| Payout Ratio | -0.55% | 1.69% | 1.90% | 2.33% | 2.52% |